We, at BioStrand, are on a mission to make omics analysis effective and available for every researcher.
Stream data to create and apply knowledge will revolutionise life sciences.
Today, genomic data analysis is a complex series of operations. Often only specially trained professionals are able to perform these analyses. Costly subscriptions to compute and store these genomic data are needed. Furthermore, omics data reside mostly in silos and integrating these omics data and meta data is difficult.
To make fundamental progress in life sciences, precision medicine, agro and food tech, these problems will have to be tackled first. We, at BioStrand, can solve these problems.
We have created a platform that makes all omics data and meta data actionable and allows analysis by everyone involved in omics research. Our goal is to provide technology that can revolutionise genetic research being done in R&D departments at pharmaceutical, biotechnology, diagnostic, agrochemical and food technology companies.
Contact us today to set up a meeting with one of our experts or request a demo.
Our Innovative Technology
BioStrand is the first company since the 1980s to come up with a completely new, out-of-the-box solution for omics data analysis. Where next generation sequencing revolutionised sequence data generation in the last decade, BioStrand now revolutionises sequence data analysis.
BioStrand offers a revolutionary methodology for identifying similarities and variations in genetic data and detecting structural anchor points that will drive innovation.
The BioStrand methodology enables unprecedented accuracy and speed of operation in detecting similarities and variations in DNA, RNA and proteins. By detecting HYFTSTM, structural 3D information is automatically integrated into the analyses, revolutionising pattern and profile detection that are critical in understanding diseases and biological processes.
With our fundamentally new method we make sure that omics data analysis finally can keep pace with data generation.
We unlock the true potential present in omics data and close the gaps towards precision medicine. Just in time.
Sign up and test Retrieve &Relate!
BioStrand was born from the recognition that omics analysis needed significant improvements.
Founded by a family team with decades of experience in medical research and healthcare, bioIT, big data and NLP, we spent seven years conducting private research about genetic analysis technology, the major barriers, and the potential opportunities. Inspired by cross-domain knowledge stemming from text analytics to evolutionary biology, we developed the formulation of hypotheses, designed algorithms to test them and further expanded our initial ideas. Step by step the project grew until we had a working prototype.
Feb 6, 2019 we founded the company and filed a patent
MVP for first platform finalised
May 15, 2020 we raised 2 M Euros in a seed round. K&E, the Holding behind Globachem invested
We welcomed our first data scientists/engineers. We received a 235 K Euros Innovation Grant from the Flemish Government
We released the beta version of R&R
We have grown to a team of 15
We released R&R 1.0 as well as the BioStrand data analysis and management platform. Publication of the white paper with the results on the Hasselt University validation study of the R&R algorithm.
Upcoming milestones: Variation analysis to be launched. Extensive NLP possibilities, prediction of 3D protein structure and protein-protein interaction
Our culture and values
Outside-the-box thinking is our natural attitude. Innovative ideas arise from creative thinking and fast failure.
Do what you say and say what you do. Achieving great things is only possible when working together in a relationship based on mutual trust and respect.
We operate in a cross-domain environment. Great achievements are always the result of teamwork. The whole is greater than the sum of its parts.
We are not only colleagues, we are the BioStrand family. Working hard also means having fun and caring for each other.
"Healthy scepticism is the basis of all accurate observation."
- Arthur Conan Doyle